FindMyKOL
Clinical trialNCT02216890CompletedPhase 1Interventional

Safety Study of SGN-CD70A in Cancer Patients

SponsorSeagen Inc.Enrollment38Diffuse, Large B-Cell, LymphomaFollicular Lymphoma, Grade 3Mantle-Cell LymphomaRenal Cell Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given to patients without causing unacceptable side effects. The pharmacokinetics and antitumor activity of SGN-CD70A will also be evaluated.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama at Birmingham

    Birmingham, Alabama, United States

  • City of Hope National Medical Center

    Duarte, California, United States

  • Cardinal Bernardin Cancer Center / Loyola University Medical Center

    Maywood, Illinois, United States

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, United States

  • Karmanos Cancer Institute / Wayne State University

    Detroit, Michigan, United States

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada, United States

  • James P. Wilmot Cancer Center / University of Rochester Medical Center

    Rochester, New York, United States

  • Unc Lineberger Comprehensive Cancer Center / University of North Carolina

    Chapel Hill, North Carolina, United States

  • University of Cincinnati Cancer Institute

    Cincinnati, Ohio, United States

  • Case Western Reserve University / University Hospitals Case Medical Center

    Cleveland, Ohio, United States

  • University of Pennsylvania / Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania, United States

  • Medical University of South Carolina/hollings Cancer Center

    Charleston, South Carolina, United States

  • Texas Oncology - Austin Midtown

    Austin, Texas, United States

  • Methodist Cancer Center

    Houston, Texas, United States

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas, United States

  • Seattle Cancer Care Alliance / University of Washington

    Seattle, Washington, United States

  • Northwest Cancer Specialists, P.C.

    Vancouver, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SGN-CD70A
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2014
Primary completion
15 Feb 2017
Completion
15 Feb 2017
Last update posted
19 Apr 2018
Registered enrollment
38
Registry id
NCT02216890

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.